Tailored therapy for severe asthma by Francesco Menzella et al.
Menzella et al. Multidisciplinary Respiratory Medicine 2015, 10:1
http://www.mrmjournal.com/content/10/1/1REVIEW Open AccessTailored therapy for severe asthma
Francesco Menzella1*, Mirco Lusuardi2, Carla Galeone1 and Luigi Zucchi1Abstract
Patients with severe asthma or COPD have often a suboptimal symptom control due to inadequate treatment. A
better understanding of pathogenetic mechanisms, phenotypes, endotypes and the new technologies available in
the fields of molecular biology and immunogenetics have made it possible to synthesize specific monoclonal
antibodies virtually able to interact with any target antigen, or to open a way for new therapeutic target options.
At the moment, the only biologic drug available in clinical practice is omalizumab. To overcome the limits of
omalizumab, the research has focused on new monoclonal antibodies presenting higher avidity for IgE (e.g. ligelizumab
and lumiximab) and ability to interact also with low affinity IgE receptor (FcεRII). At present, many new biological drugs
with different mechanisms of action and targets are matter of research. It is very important to identify the asthmatic
phenotype in order to select the most appropriate drug for the individual patient. The most promising agents are
targeted against cytokines of Th2 pattern and related receptors, such as IL-2 (daclizumab) and IL-13 (lebrikizumab)
or IL-5 in patients with hypereosinophilia (mepolizumab, reslizumab and benralizumab). Other interesting drugs
have as a target TNF-α or its soluble receptor (infliximab, golimumab and etanercept) or IL-1 (canakinumab), a
cytokine with an important systemic proinflammatory action. Finally, the discovery of increased levels of C5a in the
airways of asthmatic patients has led to the synthesis of a specific monoclonal antibody (eculizumab). Further
help should come from the identification of biomarkers that can guide in choosing the best treatment for the
individual patient, such as IgE for omalizumab or periostin for lebrikizumab.
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Patients with severe asthma have often a suboptimal
symptom control due to inadequate therapeutic options.
Actually, there is an increasing need to identify new
molecules effective to overcome treatment limitations,
particularly through the remarkable implementation of
the research in the pathophysiology and immunology
fields.
The earliest and most important pathophysiological
mechanism of asthma is represented by airways inflam-
mation, predisposing to exacerbations and probably to
bronchial remodelling [1]. It is well known that asthma
is a complex disorder with many different phenotypes
whose definition is based on clinical, inflammatory or
causative factors [2]; and heterogeneous inflammatory
profiles have been described, such as eosinophilic, neu-
trophilic and paucigranulocytic [3]. A better knowledge* Correspondence: menzella.francesco@asmn.re.it
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The discovery of different patterns of inflammation and
the transition to the next level of complexity by molecular
phenotyping and development of biomarkers [4,5] have led
to a further and significant step forward, thanks to new
technologies in molecular biology and immunogenetics.
These findings have made it possible to synthesize specific
monoclonal antibodies [MoAb(s)] interacting with any tar-
get antigen and have opened the way for the development
of tailored therapeutic options. omalizumab is the first and,
at present, the only MoAb available in clinical respiratory
medicine for the treatment of asthma. The biological drugs
studied so far (Table 1) have also shown to be effective
in other respiratory diseases or allergic reactions, such
as Churg-Strauss syndrome, hypereosinophilic syndrome,
eosinophilic pneumonia, nasal polyposis, or atopic derma-
titis, with promising perspectives in the clinical setting.al. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Omalizumab IgE Approved Subcutaneous
Quilizumab IgE IIa Subcutaneous
Ligelizumab IgE IIa Subcutaneous
Lumiliximab FcεRII (CD23) II/III Oral
Daclizumab IL2-R (CD25) II Intravenous
Lebrikizumab IL-13 III Subcutaneous
Mepolizumab IL-5 III Intravenous/Subcutaneous
Reslizumab IL-5 III Intravenous
Benralizumab IL-5 IIb Intravenous
Mogamulizumab CCR4 III Intravenous
Infliximab TNF-α II Intravenous




Eculizumab C5a II Intravenous
Canakimumab IL-1ß IIb Subcutaneous
SNG001 (Inhaled
IFN-β 1a)
IFN- β II Inhalation
Figure 1 Mechanism of action of omalizumab (Modified from [9]).
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Based on currently available data, the IgE are at the heart of
the immuno-allergen-induced inflammation. Omalizumab
(Xolair®) is a murine monoclonal antibody (MAE11) pro-
duced with the somatic cells hybridization method, whose
main characteristic is a paratope that can bind to high
(FcεRI) and low affinity (FcεRII) IgE receptors on the
cell membrane of basophils and mast cells, inhibiting
the degranulation and activation of cellular mediators
(Figure 1). Several clinical trials have been recently per-
formed in order to evaluate the clinical effectiveness of
omalizumab in severe allergic uncontrolled asthma pa-
tients. These studies have shown its effectiveness and
safety, with a significant reduction in the rate of asthma
exacerbations (up to 50%), improvement of quality of life
scores [6] and steroid-sparing effect [6]. Omalizumab dos-
age is based on total IgE levels combined with body weight
[7]. At the moment, there are no validated biomarkers
identifying potential responders among patients with
asthma, with a promising exception represented by perios-
tin according to some recent data [8].
The effectiveness of omalizumab has been recently dem-
onstrated in non-allergic asthma patients on long-term
treatment [10]. These data support the hypothesis of a
local production of IgE without systemic sensitization [11].
Other authors confirmed the efficacy of omalizumab in
children with severe asthma living in urban centers in the
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as urticaria, atopic dermatitis, allergy to Hymenoptera
venom, oculorhinitis, sinusitis, allergic bronchopulmonary
aspergillosis, and Churg-Strauss syndrome (CSS) [14].
Omalizumab has been used in CSS and uncontrolled
asthma patients on high-dose steroid therapy, with ex-
cellent results in terms of asthma control and significant
decrease in peripheral eosinophilia [15]. There were also
some reports on CSS development related to the adminis-
tration of anti-IgEMoAb, probably due to the reduction
of systemic steroids rather than to omalizumab [16].
An interesting case report showed positive results with
omalizumab in a patient with relapsing chronic eosino-
philic pneumonia (CEP), asthma, allergic sensitization
to mites and pollens and high levels of IgE, without re-
currence of CEP after 15 months of anti-IgE treatment
[17]. A flow cytometry analysis showed alterations in the
expression of CD23 (FcεRII) on B lymphocytes, which can
correlate with the response to omalizumab, along with
possible effects on down-regulation of FcεRI and FcεRII
receptors [18].
According to current data, omalizumab is indicated
as a regular long-term treatment: as a matter of fact,
IgE levels and FcεRI receptors increase after 3–4 weeks
from discontinuation of the drug. However, a study on
a small group of patients treated for 6 years showed a sub-
stantial clinical stability 3 years after stopping omalizumab
[19]. Two recent Italian papers also report some in-
crease in long-term clinical benefits [20,21], with good
cost-effective profile in saving healthcare resources
[21,22].
To overcome limitations of omalizumab, an expected
progress has been the production of monoclonal antibodies
with greater avidity for IgE, such as RG7449, a new hu-
manized MoAb that binds to the M1 segment of mem-
brane IgE and has as a target the B-lymphocytes before
they are activated to produce IgE [23].
The QGE031B/ligelizumab is a new humanized antibody,
highly potent inhibitor of the high affinity IgE receptor
(FceRI). As determined by surface Plasmon resonance,
QGE031B has a Kd = 130 pM for human IgE, represent-
ing an almost 50-fold improvement in affinity for human
IgE as compared to omalizumab (Kd = 6.8 nM).
The effectiveness of QGE031B is being assessed in pa-
tients with allergic asthma, (4/5 clinical severity stage ac-
cording to GINA guidelines), in a phase IIa clinical trial,
with omalizumab as active comparator.
Lumiliximab is another promising agent, a humanized
anti CD23 IgG1 antibody (IDEC-152) used successfully in
recurrences of lymphocytic leukemia [24]. Due to its abil-
ity to reduce the concentration of circulating IgE through
the activation of FcεRII (CD23) it has been tested in pa-
tients with mild asthma, but without particularly signifi-
cant clinical outcomes.Th2 lymphocytes and their citokyne pattern
It has long been known that asthma is a disease linked
to the activation of helper Th2-lymphocytes (whose key
cytokines are mainly IL-2, IL-3, IL-4, IL-5, IL-9, IL-13
and GM-CSF) with a concomitant lack of inhibition by
Treg lymphocytes for defective production of IL-10 [25,26].
Soluble receptors can be a potential target for new drugs,
being the immunoglobulin fusion proteins and recombin-
ant RNA able to interfere with the Th2 cytokines or their
receptors.
Allergen activation of Th2 cells stimulates IL-2 secretion
and the expression of its receptor IL-2R. Daclizumab is a
monoclonal antibody directed against CD25 subunit of
IL2-R that inhibits different cellular functions, such as
proliferation and cytokine production. The effects of this
drug were evaluated in a randomized clinical trial where
115 severe asthma patients were randomized to intra-
venous daclizumab or placebo and the results showed
only small improvements in lung function and asthma
control [27].
Interleukin 13 (IL-13) promotes the production of IgE
by plasma cells, the release of eosinophil chemoattractants
and the contraction of airways smooth muscle cells.
A preliminary study on patients with moderate allergic
asthma tested the use of two anti-IL-13 monoclonal anti-
bodies, one blocking the specific epitope for IL4-R and the
second binding the epitope that recognizes IL13-R. Positive
results were found only for anti IL4-R activity in terms of
reduced fall in FEV1 after allergen inhalation challenge [28].
The anti-IL-13 IgG4 monoclonal antibody lebrikizumab
was compared to placebo in uncontrolled asthma patients.
Lebrikizumab improved FEV1, particularly in the subgroup
with high values of FeNO and periostin in peripheral
blood [29]. Periostin is an indirect index of IL-13 activity
and candidates as a promising biomarker to identify
potential responders to the treatment. No differences
emerged regarding exacerbations, symptom score and
use of rescue medication.
Eosinophils and IL-5
The maturation, recruitment and survival of eosinophils
in the respiratory tract are determined by IL-3, GM-CSF,
but especially by IL-5, which has a key role in mediating
airways eosinophilic inflammation in asthmatic patients
[30]. IL-5 induces the final differentiation of activated B
cells into antibody-forming cells and enhances the prolif-
eration and differentiation of eosinophil precursors into
mature eosinophils [31]. In murine models it seems also
involved in the airways remodeling, so that the administra-
tion of antibodies antagonizing IL-5 largely prevents the
sub-epithelial and peribronchial fibrosis induced by the in-
halation of allergens [32].
Different conditions are associated with eosinophilia,
such as asthma, atopic diseases, helminth infestation, drug
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eral monoclonal antibodies such as anti-IL5 mepolizumab
(Bosatria®), reslizumab and benralizumab have been studied.
Mepolizumab is a humanized antibody that binds IgG1κ-
type IL-5 preventing its linking to the specific receptor. A
first study was conducted on the treatment of idiopathic
hypereosinophilic syndrome [33] and Churg-Strauss syn-
drome, in which a significant reduction was demonstrated
in the administration of systemic corticosteroids with a
good disease control [34].
The available data show a reduced number of exacer-
bations in steroid-dependent asthma patients with a con-
comitant reduction of sputum eosinophils; on the contrary,
lung function and bronchial hyperresponsiveness did not
improve [35]. A more recent work suggested that mepoli-
zumab administered at a dose of 75, 250 and 750 mg sig-
nificantly reduces the need for systemic steroids and the
number of exacerbations in severe eosinophilic asthma pa-
tients [36]. The efficacy of this drug in terms of improved
asthma control and discontinuation of systemic steroids
was evident only in trials focused on persistently hypereosi-
nophilic patients, confirming the need for defining asthma
phenotypes [37]. In a randomized, double-blind trial in-
volving 135 patients with severe eosinophilic asthma re-
quiring daily oral glucocorticoid therapy to maintain
control, mepolizumab had a significant glucocorticoid-
sparing effect, reduced exacerbations, and improved control
of asthma symptoms [38]. Another recent, randomized,
double-blind, double-dummy study, involved 576 patients
assigned to receive mepolizumab administered as either a
75-mg intravenously dose or a 100-mg subcutaneously
dose, or placebo every 4 weeks for 32 weeks. The rate of ex-
acerbations was reduced by 47% among patients receiving
intravenous mepolizumab and by 53% among those receiv-
ing subcutaneous mepolizumab, as compared to those re-
ceiving placebo [39].
A clinical trial tested reslizumab in poorly controlled
asthma and airways eosinophilia. A significant reduction
of sputum eosinophils was found with a parallel signifi-
cant improvement in quality of life, FEV1, and disease
control, in particular reference to a reduction of exacer-
bations [40].
Benralizumab is another drug tested in clinical trial. It
is a monoclonal antibody directed against the alpha chain
of IL-5 receptor, administered intravenously. In clinical
trials benralizumab reduced the levels of peripheral eo-
sinophils in moderate asthma patients, its effects persisting
up to 8–12 weeks [41]. Other authors demonstrated that
benralizumab induces antibody dependent cell-mediated
cytotoxicity on eosinophils and basophils, resulting in a
significant reduction of blood eosinophils and their bone
marrow precursors [42].
There are several other trials testing new molecules,
such as humanized antibody IgG1 anti-hIL-5 Ra (MEDI-563), antisense oligonucleotides, targeted monoclonal
antibodies against chemokine receptor CCR3 [43].
Chemokine receptor 4 (CCR4) is a target of mogamuli-
zumab (Poteligeo®), a defucosylated humanized monoclo-
nal antibody. It was approved in Japan in March 2012 for
the treatment of refractory T-cell leukemia, relapsing
peripheral T cell lymphoma (PTCL) and cutaneous T-cell
lymphoma [44]. Mogalizumab is currently licensed to
Amgen for developments in non-oncological indications,
and in 2011 a phase 1 study was initiated in adult asthmatic
patients [44].
The role of TNF-α
Tumor necrosis factor-alpha (TNF-α) is a cytokine with
a variety of effects such as stimulation and inhibition of
cell growth, angiogenesis, cytotoxicity, inflammation and
immunomodulation. It is therefore involved in different
inflammatory and respiratory diseases including asthma
and COPD. The interest on TNF-α has developed in the
last few years as a result of studies that showed an in-
crease of this cytokine in bronchoalveolar lavage fluid of
patients with severe asthma. The anti-TNF-α mainly in-
clude infliximab, etanercept, and golimumab; the first two
are monoclonal antibodies that bind to and inactivate
TNF-α (Figure 2), the third is a fusion protein between the
p75 TNF receptor and the Fc domain of human IgG1 that
can bind TNF-α with a half-life longer than the native
receptor.
Among clinical studies on etanercept (Enbrel®) a few
showed good results in reducing bronchial hyperreactivity
[46], whereas others poor clinical efficacy in terms of lung
function improvement and quality of life [47]. Other au-
thors showed a small but significant increase in quality of
life without differences on lung function [48]. Interesting
data have emerged from a small series of 7 overweight
women in whom infliximab improved asthma control
in terms of reduction of oral steroids, exacerbations and
hospitalizations. Overweight is a known condition of
TNF-α overexpression [49].
A trial of infliximab (Remicade®) administered to patients
with mild-to-moderate asthma showed no significant im-
provements in morning PEF, symptom score and use of
rescue medication [50]. The results of a large multicenter
trial of patients with severe asthma treated for 12 months
with golimumab (Simponi®) versus placebo have not
proved exciting, because of the failure to reduce flare-ups
and the lack of improvement in FEV1, with an unfavour-
able risk-benefit profile [51].
TNF inhibitors have also been studied in COPD, al-
though not extensively. A trial of infliximab administered
to patients with mild to moderate COPD did not show
benefits on symptom score, lung function and exacerba-
tions; an improvement of 6-minute walk test (6MWT)
in the group treated with infliximab was not statistically
Figure 2 Protein structure of infliximab (Modified from [45]).
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continued for adverse events in a high percentage of
cases (20-27%) as compared to controls (9%) [52].
An observational study conducted to evaluate the effi-
cacy of TNF-α antagonists in preventing hospitalizations
in patients with rheumatoid arthritis and COPD showed
that treatment with etanercept was associated with a re-
duction of 50% in the rate of hospitalization [53].
It must be remembered that the use of TNF-alpha in-
hibitors is potentially burdened by infectious risks, such
as reactivation of latent tuberculosis and histoplasmosis,
congestive heart failure, lymphoproliferative and demye-
linating disorders [54,55], so their application in respira-
tory diseases is further limited. Nevertheless, the studies
on TNF-alpha inhibitors should not be abandoned, given
the significant and not yet fully understood heterogeneity
of asthma that does not allow us, at the moment, to iden-
tify which phenotype could possibly benefit from these
drugs.
A new frontier in asthma treatment: the complement
system
The complement system is composed of several plasma pro-
teins playing a central role in the immune response, produ-
cing substances that are involved in the inflammatory
response cascade, causing vasodilation and increased
vascular permeability (C3a, C5a).
The plasma components of complement are present in
the circulation in an inactive form; activation may occur
through a “classical pathway” (i.e. formation of antigen-
antibody complexes) or an “alternative pathway” (mediatede.g. by endotoxins, complex polysaccharides, or IgA). The
key point is represented, in both cases, by the activation of
the C3 fraction.
Recent studies have shown that in asthmatic airways
there is an increase in C5a levels, and C5a receptor ex-
pression on bronchial epithelium and smooth muscle
cells. Furthermore, in animal (mice) preclinical trials the
inhibition of C5a cleavage improves lung function [56].
Eculizumab (Soliris®) is a new humanized IgG2/4 k
monoclonal antibody produced with the recombinant
DNA technology by the NS0 cell line. It binds to C5
preventing its cleavage by the C5 convertase and the
following formation of C5a and C5b-9 complex.
Eculizumab was approved for the treatment of paroxys-
mal nocturnal hemoglobinuria. A placebo-controlled trial
with this drug administered by inhalation for the inhibition
of intrapulmonary C5 showed a significant response in
mild allergic asthma patients, in terms of improved spir-
ometry and reduction of late allergen-induced eosinophilia
in induced sputum [56].
Proinflammatory cytokines
Interleukin 1 (IL-1) is a cytokine secreted by macrophages,
monocytes, fibroblasts and dendritic cells in response
to microbial infections through stimulation by LPS (an
endotoxin produced by gram negative bacteria), TNF
and following interaction with CD4 lymphocytes [57].
It has pro-inflammatory effects such as fever, vasodilation
and stimulation of other cytokines, e.g. IL-2 that activates
Th2 lymphocytes. There are two types of IL-1, alpha
and beta, with different molecular structure but similar
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antagonist (IL-1Ra) with a structure similar to IL-1 is a
natural inhibitor of these molecules.
In asthma, the response against aeroallergens is mainly
based on the inflammatory response of T lymphocytes,
with an important involvement of IL-1β in the inflamma-
tory signal transduction. Canakinumab (Ilaris®) is a human-
ized monoclonal antibody developed for the treatment
of a group of rare and potentially lethal autoinflamma-
tory diseases, denominated cryopyrin-associated peri-
odic syndromes (CAPS). These are represented in
particular by the familial cold autoinflammatory syn-
drome (FCAS), characterized by overproduction of IL-1
beta [56]. Canakinumab can induce a long-lasting and se-
lective blockade of IL-1 beta, blocking the inflammation
cascade in several autoimmune disorders, and has been
included in the list of “Orphan Drug” by the FDA (Food
and Drug Administration) and EMA (European Medicines
Agency) [58]. A randomized double-blind clinical trial
evaluated the safety and tolerability of canakinumab in
mild allergic asthma patients, determining its anti-
inflammatory effects on late asthmatic response after
allergen inhalation, with good results compared to pre-
treatment phase [59]. Despite these encouraging data, at
present there are no further studies in progress on the
drug, at least in asthma.
IFN-β and viral infections
Exacerbations of asthma caused by respiratory viruses are
a large unmet medical need, especially in the most severe
forms of the disease [60,61]. Patients with asthma are
more likely to develop lower respiratory tract symptoms
after an upper respiratory tract infection. Ex vivo, bron-
chial epithelial cells from asthmatic airways are more
susceptible to rhinovirus infection because of a deficient
induction of the antiviral protein IFN-β [62]. A total of
147 people with asthma on inhaled corticosteroids with a
history of virus-associated exacerbations, were random-
ized to 14-day treatment with inhaled IFN-β 1a (SNG001)
or placebo within 24 hours of developing cold symptoms
[63]. IFN-β treatment had no significant effect on asthma
symptoms as primary endpoint, although it enhanced
morning peak expiratory flow recovery, and reduced the
need for additional treatment. Although the trial did not
meet its primary endpoint, it suggests that inhaled IFN-β
is a potential treatment for virus-induced deteriorations of
asthma in difficult-to-treat patients [63].
Conclusions
Asthma is a complex syndrome characterized by several
phenotypic variants with different pathophysiological mech-
anisms and involvement of various cytokines. The new bio-
logical therapies have differentiated targets and mechanisms
of action, so it should be mandatory to identify the differentphenotypes and endotypes of asthma in the individual pa-
tients, in order to select the most appropriate pharmacologic
approach in terms of long-term efficacy and safety.
To do this, we need help from the identification of bio-
markers that can guide in choosing the best treatment,
moving from a generalist approach to a more “tailored”
therapy, particularly for severe asthma and other respira-
tory disorders refractory to usual care. Despite significant
progress in the latest years, both in research and clinical
application, however, the need for more effective treat-
ments in neutrophilic and steroid-resistant asthma re-
mains largely unmet.
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